Clinical trial
Protocol for the Treatment of Patients With Previously Untreated Chronic…
NCT00280241 · University of Pittsburgh, Other · Completed
Key facts
| NCT number | NCT00280241 |
|---|---|
| Title | Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia |
| Official title | Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia |
| Lead sponsor | University of Pittsburgh, Other |
| Collaborators | Genentech, Inc. Industry Biogen |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | Fludarabine, Cyclophosphamide, Rituximab |
| Enrollment | 65 |
| Start date | Jun 1, 2004 |
| Primary completion | Feb 1, 2008 |
| Completion | Jan 1, 2013 |
| First posted | Jan 20, 2006 |
| Last update posted | Feb 4, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: